Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
U.S. trial begins on hyperopic hydrogel intracorneal lens
Trois Rivieres, Quebec-Participants in a U.S. phase I clinical trial evaluating a hydrogel intracorneal lens (PermaVision, Anamed Inc., Lake Forest, CA) for the treatment of hyperopia should benefit from the changes implemented as a resultof previous international experience, said Francis Roy, MD.
Related Videos
Related Content
